Pfizer Inc. (NYSE:PFE) is one of the best low volatility large cap stocks to invest in. On November 24, Guggenheim lifted the ...

Fintel reports that on November 24, 2025, Guggenheim maintained coverage of Pfizer (NYSE:PFE) with a Buy recommendation.

JNJ’s stock has risen by almost 45%, whereas PFE has declined by 6%, greatly exceeding the S&P 500's 13% increase.

We recently published 12 Latest Stocks on Jim Cramer’s Radar . Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer ...

Pfizer has beaten its earnings per share (EPS) estimates in its past 12 quarters. Beating EPS estimates hasn't always meant positive movements for Pfizer's share price. The stock's low valuation and ...

Pfizer stock (NYSE: PFE) is currently in a significant slump, marking its ninth consecutive day of decline and losing a total of −11% of its value over that period. This sustained sell-off has wiped ...

Healthcare giant Pfizer ( PFE 2.24%) has been offering a high yield for some time. But that hasn't been enough to get ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. Pfizer (NYSE:PFE) shares are finally starting to attract ...

Pfizer Inc (NYSE:PFE) stock is up 2.6% to trade at $24.65 at last check, after the pharma giant revealed it will buy weight-loss drug company Metsera (MTSR) in a deal valued up to $7.3 billion. PFE is ...

Pfizer Inc. crushed Q2 estimates with a 36% EPS beat, proving its operational turnaround is gaining momentum despite negative market sentiment and recent stock underperformance. Aggressive ...